Related Experiment Videos
Are all 5-HT3 receptor antagonists the same?
P L Andrews1, P Bhandari, P T Davey
1St. George's Hospital Medical School, Tooting, London, U.K.
European Journal of Cancer (Oxford, England : 1990)
|January 1, 1992
Summary
Granisetron demonstrates superior antiemetic effects compared to ondansetron in ferret models. This 5-HT3 receptor antagonist shows greater potency and duration, suggesting potential clinical advantages.
Area of Science:
- Pharmacology
- Neuroscience
- Oncology
Background:
- 5-HT3 receptor antagonists are crucial antiemetics.
- Granisetron and ondansetron are key compounds in this class.
- Understanding their comparative efficacy is vital for clinical application.
Purpose of the Study:
- To compare the antiemetic activity of granisetron and ondansetron.
- To evaluate their efficacy against cisplatin-induced and radiation-induced emesis.
- To analyze pharmacological profiles and potential clinical implications.
Main Methods:
- Utilized conscious ferret models to assess emesis.
- Administered cisplatin (10 mg/kg i.v.) and whole-body X-irradiation (200 rads) to induce emesis.
- Compared the antiemetic responses to granisetron and ondansetron.
Main Results:
- Granisetron exhibited greater potency and longer duration of action than ondansetron.
- Granisetron displayed a more conventional dose-response profile.
- Pharmacological differences suggest distinct clinical performance.
Conclusions:
- Granisetron appears to be a more effective antiemetic than ondansetron in preclinical models.
- Emerging differences in potency, duration, and profile may impact clinical dosing and efficacy.
- Further head-to-head clinical trials are needed to confirm these findings in patients.